🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalIreland HSE coverage for Wegovy — 12 month update Page 5

Ireland HSE coverage for Wegovy — 12 month update

sarah.morrison Wed, Jun 4, 2025 at 1:21 PM 25 replies 1,558 viewsPage 5 of 5
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Jun 8, 2025 at 1:10 PM#21

Adding the clinical framing, because it changes how the question reads.

My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.

Last edited: Jun 8, 2025 at 3:10 PM
5 5FitDadDave, RunnerRach, TrialNerd_Beth and 2 others
Reply Quote Save Share Report
emma_london
Member
312
1,456
Oct 2024
London, UK
Jun 9, 2025 at 7:00 PM#22
Dr.AddMedPHL said:
My insurance denied my PA related to cost and coverage.

Second this.

4 4mike.trainer_LA, sarah_nash92, FitDadDave and 1 other
Reply Quote Save Share Report
pam_columbus
Member
312
1,345
Aug 2024
Columbus, OH
Jun 11, 2025 at 12:51 AM#23
Dr.AddMedPHL said:
My insurance denied my PA related to cost and coverage.
Dr.AddMedPHL said:
...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

  1. Document medical necessity (BMI, comorbidities, failed alternatives)
  2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
  3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
  4. Request peer-to-peer review between your doctor and the plan's medical director
  5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

Last edited: Jun 11, 2025 at 6:51 AM
3 3Dr.LipidDallas, alex_tucson, kevin_tulsa
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Jun 12, 2025 at 6:43 AM#24

Adding the numbers, since they settle part of this. Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.

Last edited: Jun 12, 2025 at 8:43 AM
2 2ben_calgary, patPC_UT
Reply Quote Save Share Report
ben_calgary
Member
245
1,123
Oct 2024
Calgary, CA
Jun 13, 2025 at 12:36 PM#25

Following on from Dr.AddMedPHL — and this may be the naive question:

Whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg?

Last edited: Jun 13, 2025 at 6:36 PM
1 1NauseaFreeNow
Reply Quote Save Share Report
1345

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register